NCT06522828View on ClinicalTrials.gov

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
Interventions
DRUG

SSGJ-707

SSGJ-707 is a bispecific antibody against human PD-1 and VEGF

DRUG

carboplatin

chemotherapy

DRUG

paclitaxel

chemotherapy

Trial Locations (1)

Unknown

RECRUITING

Chongqing Cancer Hospital, Chongqing

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY